adalimumab
Sign in to saveAlso known as D2E7, Ig gamma-1 chain C region, LU-200134, FKB327, Humira®, Humira
Adalimumab, sold under the brand name Humira and others, is a disease-modifying antirheumatic drug and monoclonal antibody used to treat rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis. It is administered by subcutaneous injection (injection under the skin). It works by inactivating tumor necrosis factor (TNF).
Key facts
- Drug.Verifiedfields
- changed
- Drug.verifiedrevid
- 477241856
- Drug.type
- mab
- Drug.mab_type
- mab
- Drug.source
- u
- Drug.target
- Tumor necrosis factor
- Drug.tradename
- Humira
- Drug.MedlinePlus
- a603010
- Drug.DailyMedID
- Adalimumab
- Drug.pregnancy_AU
- C
- Drug.routes_of_administration
- Subcutaneous
- Drug.class
- TNF inhibitor
- Drug.ATC_prefix
- L04
- Drug.ATC_suffix
- AB04
- Drug.biosimilars
- adalimumab-aacf, adalimumab-aaty, adalimumab-adaz, adalimumab-adbm, adalimumab-afzb, adalimumab-aqvh, adalimumab-atto, adalimumab-bwwd, adalimumab-fkjp, adalimumab-ryvk, Abrilada, Amgevita, Amsparity, Ardalicip, Cadalimab, Ciptunec, Cyltezo, Exemptia, Hadlima, Halimatoz, Hefiya, Hukyndra, Hulio, Hyrimoz, Idacio, Imraldi, Kromeya, Libmyris, Mabura, Simlandi, Solymbic, Trudexa, Yuflyma, Yusimry
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.legal_CA_comment
- / Schedule D
via Wikipedia infobox
Research
13,353 papers- AVT02: An Adalimumab Biosimilar.Clinical drug investigation · 2022
- FKB327: An Adalimumab Biosimilar.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2019
- Navigating adalimumab biosimilars: an expert opinion.Journal of comparative effectiveness research · 2023
- PF-06410293: An Adalimumab Biosimilar.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2020
- Adalimumab for CNS sarcoidosis: single-center experience and literature review.Journal of neurology · 2022
via PubMed
Wikidata facts
Show 3 more facts
- World Health Organisation international non-proprietary name
- adalimumab
- defined daily dose
- 2.9
- Commons category
- Adalimumab
via Wikidata · CC0
~17 min read
Article
19 sectionsContents
- Medical uses
- Rheumatoid arthritis
- Juvenile idiopathic arthritis
- Ankylosing spondylitis
- Crohn's disease
- Ulcerative colitis
- Plaque psoriasis
- Hidradenitis suppurativa
- Non-infectious uveitis
- Mechanism of action
- Adverse effects
- History
- Research
- Society and culture
- Economics
- Biosimilars
- Royalty litigation
- Patent litigation
- References
Adalimumab, sold under the brand name Humira and others, is a disease-modifying antirheumatic drug and monoclonal antibody used to treat rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis. It is administered by subcutaneous injection (injection under the skin). It works by inactivating tumor necrosis factor (TNF).
Common side effects include upper respiratory tract infections, pain at the site of injection, rash, and headache. Other side effects may include serious infections, cancer, anaphylaxis, reactivation of hepatitis B, new onset or exacerbation of demyelinating diseases (such as multiple sclerosis), heart failure, liver failure, and aplastic anemia. Use during pregnancy is not recommended, but some sources show use during breastfeeding may be safe.